Format

Send to

Choose Destination
Qual Life Res. 2019 May;28(5):1265-1269. doi: 10.1007/s11136-018-2089-8. Epub 2019 Jan 7.

Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03).

Author information

1
Memorial Sloan Kettering Cancer Center, New York, NY, USA. atkinsot@mskcc.org.
2
University of California-San Francisco, San Francisco, CA, USA.
3
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4
Laser Surgery Care, New York, NY, USA.
5
Montefiore Medical Center, New York, NY, USA.
6
Weill Cornell Medicine, New York, NY, USA.
7
Anal Dysplasia Clinic Midwest, Chicago, IL, USA.
8
Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Abstract

PURPOSE:

The Anal Cancer HSIL Outcomes Research (ANCHOR) trial aims to determine whether treating precancerous anal high-grade squamous intraepithelial lesions (HSIL), versus active surveillance, is effective in reducing anal cancer incidence in HIV-infected individuals. We evaluated the reliability (i.e., internal consistency, test-retest) and between-group stability of a 25-item ANCHOR Health-Related Symptom Index (A-HRSI).

METHODS:

ANCHOR participants at least 1-month post-randomization to treatment or active surveillance completed the A-HRSI via telephone. Participants were contacted 7-10 days later to complete the A-HRSI and a participant global impression of change (PGIC) item.

RESULTS:

Participants (n = 100) were enrolled (mean age = 51.4, 79% cisgender-male, 73% African American, 9% Hispanic) from five ANCHOR sites. Cronbach's α was good for the physical symptoms (0.82) domain and fair for the physical impacts (0.79) and psychological symptoms (0.73) domains. Intraclass correlation coefficients were good for each of respective domains (i.e., 0.80, 0.85, and 0.82). There were no significant differences in PGIC between the treatment (n = 56) and active surveillance (n = 44) groups (F(1,98) = 2.03, p = 0.16).

CONCLUSIONS:

The A-HRSI is able to reliably assess participant-reported symptoms and impacts of anal HSIL across a 7-10 days of timeframe. Future work will involve the establishment of construct and discriminant validity prior to inclusion in the full ANCHOR trial.

KEYWORDS:

ANCHOR trial; Clinical outcome assessments; Health-related quality of life; Neoplasms; Patient-reported outcomes

PMID:
30617704
PMCID:
PMC6472969
[Available on 2020-05-01]
DOI:
10.1007/s11136-018-2089-8

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center